phenylacetylglutamine has been researched along with Cardiovascular Diseases in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 3 (50.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, JT; Battle, S; Buffa, JA; DiDonato, JA; Dwidar, M; Fischbach, MA; Fu, X; Funabashi, M; Gogonea, V; Hajjar, AM; Hazen, SL; Keranahalli, P; Li, XS; Nemet, I; Romano, KA; Sangwan, N; Tittle, AN; Wang, Z; Zhu, Y | 1 |
Cajka, T; DiDonato, JA; Fiehn, O; Fischbach, MA; Funabashi, M; Gupta, N; Hazen, SL; Li, L; Mohan, ML; Naga Prasad, SV; Nemet, I; Ramer-Tait, AE; Rey, FE; Romano, KA; Saha, PP; Skye, SM; Tang, WHW; Wu, Y; Zhu, W | 1 |
Hazen, SL; Weeks, TL; Witkowski, M | 1 |
Banerjee, T; Coresh, J; Hostetter, TH; Hwang, S; Melamed, ML; Meyer, TW; Plummer, NS; Powe, NR; Shafi, T; Sirich, TL | 1 |
Banerjee, T; Coresh, J; Hostetter, TH; Hwang, S; Melamed, ML; Meyer, TW; Parekh, RS; Powe, NR; Shafi, T | 1 |
Augustijns, P; Claes, K; de Loor, H; Evenepoel, P; Kuypers, D; Meijers, B; Poesen, R | 1 |
1 review(s) available for phenylacetylglutamine and Cardiovascular Diseases
Article | Year |
---|---|
Gut Microbiota and Cardiovascular Disease.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cardiovascular Diseases; Carnitine; Choline; Disease Models, Animal; Fatty Acids, Volatile; Fecal Microbiota Transplantation; Feces; Gastrointestinal Microbiome; Glutamine; Host Microbial Interactions; Humans; Methylamines; Mice; Mice, Inbred C57BL; Signal Transduction; Thrombosis; Vasculitis | 2020 |
1 trial(s) available for phenylacetylglutamine and Cardiovascular Diseases
Article | Year |
---|---|
Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.
Topics: Adult; Aged; Cardiovascular Diseases; Cresols; Female; Glutamine; Hippurates; Humans; Indican; Kidney Failure, Chronic; Longitudinal Studies; Male; Middle Aged; Renal Dialysis; Risk Factors; Serum Albumin; Sulfuric Acid Esters; Uremia | 2017 |
4 other study(ies) available for phenylacetylglutamine and Cardiovascular Diseases
Article | Year |
---|---|
Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Gastrointestinal Microbiome; Glutamine; Mice | 2023 |
A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors.
Topics: Animals; Arteries; Bacterial Proteins; Blood Platelets; Cardiovascular Diseases; Death, Sudden, Cardiac; Gastrointestinal Microbiome; Glutamine; Humans; Male; Metabolome; Metabolomics; Mice; Myocardial Infarction; Platelet Activation; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Risk Factors; Stroke; Thrombosis | 2020 |
Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Cresols; Female; Glutamine; Hippurates; Humans; Indican; Kidney Failure, Chronic; Male; Middle Aged; Morbidity; Mortality; Patient Outcome Assessment; Renal Dialysis; Sulfuric Acid Esters; United States | 2015 |
Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD.
Topics: Adult; Aged; Cardiovascular Diseases; Female; Glutamine; Humans; Male; Microbiota; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic | 2016 |